

64th ASH Annual Meeting 2022 – Overview of CML related sessions

Timings: CST (Central Standard Time)

Location: Ernst N. Memorial Convention Center, New Orleans

Time slots	Sessions
iCMLf Sessions	
Dec 9 (Friday) 12.00 - 3.00 p.m. Riverside Hampton Inn and Suites New Orleans Convention Center	iCMLf Forum: The Next Big Challenges in CML? Chair: Timothy Hughes (SAHMRI/ University of Adelaide) Topics: <ol style="list-style-type: none"> 1. The CML Cell Environment Professor Michael Deininger (Medical College of Wisconsin, USA) 2. Persistence in CML Assistant Professor Ted Braun (Oregon Health & Science University, USA) 3. Resistance in CML Professor Jorge Cortes (University of Augusta, USA) Panellists: <ul style="list-style-type: none"> • Lisa Machado (Canadian CML Network, Canada) • Professor Jane Apperley (Imperial College London, UK) • Professor Timothy Hughes (SAHMRI/University of Adelaide, Australia)
Dec 12 (Monday) 6.00 – 8.00 p.m. Ernest N. Morial Convention Center (Hall D)	Poster presentation iCMLf CML and COVID-19 CANDID data Sub-analysis on the interaction of molecular response and other risk factors Poster no. 4327: A Risk Model for CML Patients with COVID-19: Importance of Molecular Response in the Context of Age, Comorbidities and Country Income (Radich JP et al.)
Satellite Symposia	
Dec 9 (Friday) 7.00 – 10.00 a.m. Sheraton New Orleans (Napoleon C)	Satellite Symposium: The Sequel to the Targeted Therapy Era in CML: Guidance on Sequential Care and Integrating Established and Novel Options into Cohesive Management Plans Sponsor: Novartis Pharmaceuticals Corporation Chair: Vivian Oehler (Fred Hutchinson Cancer Center)

Time slots	Sessions
	<p>Speakers:</p> <ul style="list-style-type: none"> • Michael Mauro (Memorial Sloan Kettering Cancer Center) • Kendra Sweet (Moffitt Cancer Center)
<p>Dec 9 (Friday) 7.00 – 10.00 a.m.</p> <p>Ernest N. Morial Convention Center (Great Hall AD)</p>	<p>Satellite Symposium: Navigating the Frontier of Hematologic Malignancies Therapies</p> <p>Sponsors:</p> <ul style="list-style-type: none"> • An independent educational grant from AstraZeneca Pharmaceuticals LP • Additional funding provided by The Leukemia & Lymphoma Society <p>Chair: Helen E. Heslop (Baylor College of Medicine)</p> <p>Speakers:</p> <ul style="list-style-type: none"> • Katherine Donovan (Dana Farber Cancer Institute) • Soheil Meshinchi (Fred Hutchinson Cancer Center) • Mark Roschewski (National Cancer Institute) • Saad Usmani (Memorial Sloan Kettering Cancer Center) <p>Program:</p> <ul style="list-style-type: none"> • Bispecific Antibodies: Promising Therapeutics for Multiple Myeloma • New Strategies for T Cell Immunotherapy: "Off-the-Shelf" T Cell Therapies in the Era of CAR-T • Targeting Intracellular Proteins: PROTACs in the Management of Hematologic Cancers • Antibody-Drug Conjugates: Overcoming Limitations in the Management of AML • Risk Prediction and Individualized Therapy: Role of ctDNA in DLBCL
<p>Dec 9 (Friday) 11.00 a.m. – 2.00 p.m.</p> <p>Hyatt Regency New Orleans (Celestin EFGH)</p>	<p>Satellite Symposium: Elevating Equity in Caring for Patients with Hematologic Malignancies</p> <p>Sponsors: AstraZeneca, Bristol Myers Squibb, Genentech, GlaxoSmithKline, Legend Biotech, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc., Regeneron Pharmaceuticals, Gilead Sciences, Inc., and Lilly</p> <p>Chair: Adrienne A. Phillips (Division of Hematology and Oncology, Department of Medicine, Weill Cornell Medicine/New York Presbyterian Hospital)</p> <p>Speakers:</p> <ul style="list-style-type: none"> • Laura Ortiz-Ravick (Director, Outreach and Health Promotion, The

Time slots	Sessions
	<p>Leukemia & Lymphoma Society)</p> <ul style="list-style-type: none"> Amber Thomassen (Clinical Operations APP Team Manager Sylvester Comprehensive Cancer Center University of Miami) <p>Program:</p> <p>This 90-minute live symposium, developed through a collaboration between Medscape Oncology and The Leukemia & Lymphoma Society is designed to increase awareness of health disparities for clinicians treating patients with hematologic malignancies from diverse backgrounds and provide strategies for overcoming barriers to equitable care. A multidisciplinary panel consisting of a hematologist/oncologist, nurse practitioner and patient advocate will provide a comprehensive review of specific issues that affect patients with hematologic malignancies, including guidance for community practice, clinical strategies to address disparities, healthcare policies, and patient access considerations.</p>
Education Program	
<p>Dec 11 (Sunday) 4.30 – 5.45 p.m. Ernest N. Morial Convention Center (Ballroom C)</p>	<p>Education Session: Beyond Routine Frontline Therapy of CML</p> <p>Chair: Timothy Hughes (Adelaide, Australia)</p> <p>Program:</p> <ul style="list-style-type: none"> Treatment of TKI resistant chronic phase CML (Timothy Hughes, Adelaide, Australia) Transplantation in CML in the TKI era: Who, When, How? (Nicolaus Kroeger, Hamburg, Germany) Treatment of CML in Pregnancy (Jane Apperley, London, UK)
Scientific Program	
<p>Dec 11 (Saturday) 4.00 – 5.35 p.m. Ernest N. Morial Convention Center (R02—R05)</p>	<p>JOINT Session: Seed and Soil: The Role of Inflammation in Myeloid Malignancies</p> <p>Sponsors:</p> <ul style="list-style-type: none"> Scientific Committee on Myeloid Biology Scientific Committee on Myeloid Neoplasia <p>Chair: Kimberly Stegmaier (Dana-Farber Cancer Institute)</p> <p>Program:</p> <ul style="list-style-type: none"> Inflammatory Signaling and Clonal Hematopoiesis (Katherine Y King, Houston, TX) Contribution of the Bone Marrow Microenvironment to Leukemogenesis (Cristina Lo Celso, London, UK) Dysregulated Inflammatory Signaling in the Pathogenesis of Myeloid

Time slots	Sessions
	<p>Malignancies (Eric M Pietras, University of Colorado Anschutz Medical Campus, Aurora, CO)</p> <ul style="list-style-type: none"> Therapeutic Implications of Inflammatory Signaling in Myeloid Malignancies (Daniel T. Starczynowski, Cincinnati Children's Hospital, Cincinnati, OH)
Oral Sessions	
<p>Dec 10 (Saturday) 9.30 – 11.00 a.m. Ernest N. Morial Convention Center (217- 219)</p>	<p>Oral Session: Chronic Myeloid Leukemia: Clinical and Epidemiological: Novel Agents</p> <p>Moderators:</p> <ul style="list-style-type: none"> David T Yeung (University of Adelaide, Australia) Michael Mauro (Memorial Sloan Kettering Cancer Center, New York, USA) <p>Program:</p> <ul style="list-style-type: none"> 9.30 a.m.: Early and Deep Molecular Responses Achieved with Frontline Asciminib in Chronic Phase CML – Interim Results from ALLG CML13 Ascend-CML (Yeung DT et al.) (79) 9.45 a.m.: Efficacy and Safety Results from ASC4MORE, a Randomized Study of Asciminib (ASC) Add-on to Imatinib (IMA), Continued IMA, or Switch to Nilotinib (NIL) in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Not Achieving Deep Molecular Responses (DMRs) with ≥ 1 Year of IMA (Cortes JE et al.) (80) 10.00 a.m.: A Five-Year Follow-up on Safety and Efficacy of Olverembatinib (HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML) in China (Jiang Q et al.) (81) 10.15 a.m.: Olverembatinib (HQP1351) Overcomes Ponatinib Resistance in Patients with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) (Jabbour E et al.) (82) 10.30 a.m.: Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation (Jiang Q et al.) (83) 10.45 a.m.: Efficacy and Safety of Vodobatinib in Patients (pts) with Chronic Phase Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML): A Sub Group Analysis By Lines of Tyrosine Kinase Inhibitor (TKI) Therapy (Cortes JE et al.) (84)

Time slots	Sessions
Dec 10 (Saturday) 9.30 – 11.00 a.m. Ernest N. Morial Convention Center (353-355)	Oral Session: Myeloid Oncogenesis: Basic: Therapeutic Targeting of Myeloid Malignancies Moderator: <ul style="list-style-type: none"> • Andre Catic (Baylor College of Medicine) • Ann Mullally (Brigham and Women's Hospital) Program: <ul style="list-style-type: none"> • 10.45 a.m.: TIF1β Enhances Self-Renewal Capacity of BCR-ABL Leukemic Stem Cells and Inhibits the Myeloid Differentiation (Morii M et al.) (42)
Dec 10 (Saturday) 2.00 – 3.30 a.m. Ernest N. Morial Convention Center (343-345)	Oral Session: Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Targeted Protein Degradation and Emerging Small Molecule Inhibitors in Myeloid Neoplasms Moderators: <ul style="list-style-type: none"> • Elvin Wagenblast (Icahn School of Medicine) • Valeria Visconte (Cleveland Clinic) Program: <ul style="list-style-type: none"> • 2.15 p.m.: LPA81: Discovery of an Exceptionally Potent Protac Degrading Native and Mutant BCR-ABL1 Oncoprotein in CML (Rouhimoghadam M et al.) (200)
Dec 10 (Saturday) 4.00 – 5.30 p.m. Ernest N. Morial Convention Center (265-268)	Oral Session: Chronic Myeloid Leukemia: Clinical and Epidemiological: Molecular Predictors and Advanced Phase Diseases Moderators: <ul style="list-style-type: none"> • Douglas Smith (Johns Hopkins University School of Medicine) • Nobuko Hijiya (Columbia University Medical Center) Program: <ul style="list-style-type: none"> • 4.00 p.m.: Additional Mutational Events at Diagnosis of CML Confer Inferior Failure-Free Survival and Molecular Response for Patients Treated with Frontline Imatinib but Not for Patients Treated with Frontline Second-Generation Tyrosine Kinase Inhibitors (Shanmunagathan N et al.) (331) • 4.15 p.m.: ASXL1 Mutations Predict Inferior Molecular Response to Nilotinib Treatment in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase (Ernst T et al.) (332) • 4.30 p.m.: Outcome of Third-Line Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in Chronic Phase: A

Time slots	Sessions
	<p>Propensity Score Analysis (Jabbour E et al.) (333)</p> <ul style="list-style-type: none"> 4.45 p.m.: Somatic Mutations in Myeloid Transcription Factors and in Activated Signaling Pathway, but Not in Epigenetic Modifier Pathway, Predict the Risk of Treatment Failure and Progression to Advanced Phase in Chronic Myeloid Leukemia (Kim T et al.) (334) 5.00 p.m.: Is the 2nd Generation Tyrosine Kinase-Inhibitor a Better Initial Therapy Than Imatinib in Persons with Chronic Myeloid Leukemia Presenting in Accelerated Phase: A Multicenter Retrospective Study (Yang S et al.) (335) 5.15 p.m.: Treatment and Disease Characteristics of Chronic Myeloid Leukemia in Blast Crisis: The European Leukemianet Blast Crisis Registry (Brioli A et al.) (336)
<p>Dec 10 (Saturday) 4.00 – 5.30 p.m. Ernest N. Morial Convention Center (275-277)</p>	<p>Oral Session: Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational Identification of Novel Therapeutic Targets in MPN and CML</p> <p>Moderators:</p> <ul style="list-style-type: none"> Anna E Marneth (Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School) Bethan Psaila (Molecular Haematology Unit, Brigham and Women's Hospital, Harvard Medical School) <p>Program:</p> <ul style="list-style-type: none"> 4.00 p.m.: A Single-Cell Atlas Identifies Pretreatment Features of Primary Imatinib Resistance in Chronic Myeloid Leukemia (Krishnan V et al.) (325) 4.45 p.m.: Integrated High-Throughput Drug Profiling and CRISPR Screening Identify Novel Pathway Vulnerabilities of Leukemic Stem Cells in Chronic Myeloid Leukemia (Adnan-Awad S et al) (328)
<p>Dec 10 (Saturday) 4.00 – 5.30 p.m. Ernest N. Morial Convention Center (220-222)</p>	<p>Oral Session: Outcomes Research – Myeloid Malignancies I</p> <p>Moderators:</p> <ul style="list-style-type: none"> Wellington Fernandes da Silva (Universidade de Sao Paulo) Diego Adrianzen Herrera (University of Vermont) <p>Program:</p> <ul style="list-style-type: none"> 5.15 p.m.: Therapy in Patients with Chronic Myeloid Leukemia Outside of Clinical Trials: Results of the German CML-Registry (CML-VI) (Kohlbrenner K et al.) (390)
<p>Dec 10 (Saturday)</p>	<p>Oral Session: Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities III</p>

Time slots	Sessions
4.00 – 5.30 p.m. Ernest N. Morial Convention Center (343-345)	Moderators: <ul style="list-style-type: none"> • Boglarka Gyurkocza (Memorial Sloan Kettering Cancer Center) • Shernan G Holtan (University of Minnesota) Program: <ul style="list-style-type: none"> • 5.00 p.m.: Gvhd Prophylaxis Incorporating Methotrexate in Allo-HCT for Chronic Myeloid Malignancies and sAML: A Retrospective Analysis from the CmwP of the EBMT (Luft T et al.) (371)
Dec 11 (Sunday) 4.30 – 6.00 p.m. Ernest N. Morial Convention Center (388-390)	Oral Session: Chronic Myeloid Leukemia: Clinical and Epidemiological: Longer Term Response, TR, Pregnancy, and Disparities Moderators: <ul style="list-style-type: none"> • Jorge Cortes (Georgia Cancer Center, Augusta University) • Carmen Fava (University of Turin) Program: <ul style="list-style-type: none"> • 4.30 p.m.: Long-Term Follow-up of Low-Dose Dasatinib (50mg Daily) As Frontline Therapy in Newly Diagnosed Chronic Myeloid Leukemia (Gener-Ricos G et al.) (619) • 4.45 p.m.: Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (Cortes JE et al.) (620) • 5.00 p.m.: Chronic Myeloid Leukemia Diagnosed during Pregnancy: How to Manage? Description of 86 Cases from ELN International Registry (Chelysheva EJ et al.) (621) • 5.15 p.m.: Efficacy of Ropoginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia – an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group (Burchert A et al.) (622) • 5.30.p.m.: Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation: The Tfr-PRO Study (Gambacorti-Passerini C) (623) • 5.45 p.m.: Racial and Ethnic Disparities in Survival Outcomes in Chronic Myeloid Leukemia (Sobieski CE et al.) (624)
Poster Sessions	
Dec 10 (Saturday) 5.30 – 7.30 p.m.	Poster Session: Chronic myeloid leukemia Clinical and epidemiological: Poster I Poster:

Time slots	Sessions
Hall D	<ul style="list-style-type: none"> • 1689: A Phase II Study of the Combination of Decitabine, Venetoclax and Ponatinib in Patients with Chronic Myeloid Leukemia (CML) in Myeloid Blast Phase (MBP) or Philadelphia-Chromosome Positive (Ph+) Acute Myeloid Leukemia (AML) (Senapati J et al.) • 1690: Minimally Invasive Blood Sampling for <i>BCR::ABL1</i> transcript Monitoring (Oehler V et al.) • 1691: Asciminib As Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)-H. Jean Khoury Cure CML Consortium Study (Atallah E et al.) • 1692: Kinase Domain Mutation Testing and Clinical Outcome in a Nationwide Chronic Myeloid Leukemia Patient Population (Kockerols CB et al.) • 1693: Effectiveness of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after Two or More Prior Tyrosine Kinase Inhibitors (Žácková D et al.) • 1694: Subjects with Chronic Myeloid Leukemia Identified As Intermediate- or High-Risk Subjects Using the Imatinib Therapy Failure (IMTF) Model Benefit from Initial Therapy with a Second-Generation Tyrosine Kinase Inhibitor (Zhang X et al.) • 1695: Prognostic Model of Transformation to Blast Phase in Patients with Chronic Myeloid Leukemia (Bataller A et al.) • 1696: More Than Ten Years Follow-up of Frontline Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myeloid Leukemia (Haddad F et al.) • 1967: Duration of \geqMR4 Is the Best Predictor for a Successful 1st Treatment-Free Remission (TRF1) Attempt in CML Patients Treated with Tyrosine Kinase Inhibitors (TKI); Long-Term Follow-up of a Large Cohort of Patients Including a Cohort Undergoing a 2nd Tfr (TFR2) Attempt (Schwarer JA et al) • 1968: Long-Term Molecular Testing and Clinical Response of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase: 5-Year Follow-up from SIMPLICITY, a Prospective, Observational Study (Cortes JE et al.) • 1699: Chip-Based Digital PCR Platform, Lab on an Array, the Newly Developed Highly Accurate and Sensitive Method for the Detection of BCR-ABL1 Transcripts in Chronic Myeloid Leukemia (Song HW et al.) • 1700: Permanent Discontinuation of Tyrosine Kinase Inhibitor Frontline Therapy in Patients with Chronic Phase Chronic Myeloid Leukemia Patients during the First 36 Months of Treatment: A “Campus CML” Study (Latagliata R et al.) • 1701: Real-World Data Analysis of the Molecular Response Kinetics within the Two First Years of the RELMC-NOVA Study in Newly

Time slots	Sessions
	<p>Diagnosed Spanish CML-CP Patients Treated with Tyrosine Kinase Inhibitors (TKIs) in First Line (Casado Montero LF et al)</p> <ul style="list-style-type: none"> • 1702: Chronic Myeloid Leukemia in Adolescents and Young adults: Clinicopathological Variables and Outcomes (Abdul-Jaber Abdulla M et al.) • 1703: Efficacy and Safety of Bosutinib Vs Imatinib By Charlson Comorbidity Index in Newly Diagnosed Patients with Chronic Myeloid Leukemia (Deininger MW et al.) • 1704: Clonal Hematopoiesis Detected at the Time of Tyrosine Kinase Inhibitor Cessation Is Associated with Delayed Molecular Recurrence after Treatment-Free Remission in Patients with CML (Branford S et al.) • 1705: Treatment-Free Remission in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib Front-Line, in Real-Life Conditions: Influence of Switching to Another TKI Prior to Cessation (Nicolini FE et al.) • 1706: Choice of Tyrosine Kinase Inhibitor and Early Events during the First Year of Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Patients with Concomitant Diabetes: A “Campus CML” Study (Capodanno I et al.) • 1707: Analysis of Immunological and Clinical Response to Vaccination Against Sars-COV-2 in Patients with Chronic Myeloid Leukemia (Castronuño AZ et al.) • 1708: Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors (Pérez-Lamas L et al.)
<p>Dec 10 (Saturday) 5.30 – 7.30 p.m. Ernest N. Morial Convention Center (Hall D)</p>	<p>Poster Session: Outcomes Research – Myeloid Malignancies: Poster I Poster</p> <ul style="list-style-type: none"> • 2303: Experiences and Views of Leukemia Patients: A Global Survey (Pemperton-Whiteley Z et al.) • 2306: Health-Related Quality of Life and Financial Burden of Ethiopian Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors (Efficace F et al.) • 2311: Global Representation in Phase 2 and Phase 3 Clinical Trials for Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia (Casey M et al.)
<p>Dec 11 (Sunday) 6.00 – 8.00 p.m. Ernest N. Morial Convention</p>	<p>Poster Session: Chronic Myeloid Leukemia Clinical and epidemiological: Poster II Poster:</p> <ul style="list-style-type: none"> • 3008: Dynamics of Response and Response Factors in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Time slots	Sessions
Center (HallD)	<p>after ≥ 2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 Ascembl Study (Hughes T et al.)</p> <ul style="list-style-type: none"> • 3009: Molecular Response of $\leq 10\%$ BCR::ABL1^{IS} Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial (Apperley JF et al.) • 3010: Trends in Frontline Treatment and Overall Survival in the Era of Targeted Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia (Vardell VA et al.) • 3011: Treatment Free Remission after Combination Therapy with Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed after a Prior Attempt at TKI Discontinuation-H Jean Khoury Cure CML Consortium Study (Mauro M et al.) • 3012: ASC4FIRST: A Phase III Study of Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitor in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) (Hughes T et al.) • 3013: Comedication of Proton Pump Inhibitors and Dasatinib Is Common in CML but XS004, a Novel Amorphous Solid Dispersion Formulation of Dasatinib, Provides Improved Uptake and Low pH-Dependency, Minimizing Unwanted Drug-Drug Interactions (Larfors G et al.) • 3014: Population Pharmacokinetics in Hepatic and Renal Impairment and PBPK Drug-Drug Interaction Simulations of Asciminib, a Novel Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia in Chronic Phase (Combes FP et al.) • 3015: The Prognostic Impact of HMGCLL1 Gene Variant on Treatment Outcomes in Chronic Myeloid Leukemia (CML) Patients: Adverse Impact on the Response, Failure, and Progression with Imatinib Which Can be Abrogated By the Use of 2nd Generation Tyrosine Kinase Inhibitor (TKI) Upfront Therapy (Perusini MA et al.) • 3016: Last Interim Results of the Real-Life Study Evaluating the Efficacy and Safety of Ponatinib "Topase" in Patients with TKI-Resistant or Intolerant CML (Cayssials E et al.) • 3017: Risk Factor Analysis for Second Treatment-Free Remission Failure from the Canadian TKI Discontinuation (TRAD) Trial in CML Patients: Treatment-Free Remission Accomplished By Dasatinib (Perusini MA et al.) • 3018: First-in-Human Study of Elvn-001, a Highly Selective BCR::ABL1 Tyrosine Kinase Inhibitor, in Patients with Chronic Myeloid Leukemia Who Failed Previous Tyrosine Kinase Inhibitor Therapies (Hughes T et al.)

Time slots	Sessions
	<ul style="list-style-type: none"> • 3019: Somatic Mutations Are Frequently Detected in CML Patients before Treatment-Free Remission (TFR) Attempt with Tyrosine Kinase Inhibitor (TKI) Discontinuation but with Uncertain Predictive Value for Tfr Failure (Perusini MA et al.) • 3020: ASC2ESCALATE: A Phase 2, Single-Arm, Dose-Escalation Study of Asciminib Monotherapy in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with 1 Prior Tyrosine Kinase Inhibitor (TKI) (Sasaki K et al.) • 3021: ASC4START: A Phase IIIb, Open-Label, Randomized Study of Tolerability and Efficacy of Asciminib Versus Nilotinib in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia in Chronic Phase (Hochhaus A et al.) • 3022: Low Dose Dasatinib Is Not As Active in a CML CP Cohort Enriched with Intermediate/High-Risk CML Chronic Phase: A Phase IIb Multi-Center Trial (Abraham A et al.) • 3023: Justification for Asciminib Dosing in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (Ph+ CML-CP) with and without the T315I Mutation (Combes FP et al.) • 3024: Chronic-Phase Chronic Myeloid Leukemia Times to Death By Disease Support Tyrosine Kinase Inhibitor Dose Reductions When BCR::ABL1 Level Is <1% and Decreasing (Radiovovayevitch T et al.) • 3025: Real-World Experience of Asciminib: Factors Associated with Response (Innes A et al.) • 3016: Efficacy and Safety of Bosutinib Versus Imatinib in US Patients with Newly Diagnosed Chronic Myeloid Leukemia after 5-Years Follow-up in the Bfore Trial (Kota V et al.) • 3027: Clinical Outcomes of Chronic Myeloid Leukaemia (CML) Patients on Asciminib through the Managed Access Program (MAP) in Australia (Chee L et al)
Dec 11 (Sunday) 6.00 – 8.00 p.m. Ernest N. Morial Convention Center (Hall D)	Poster Session: Outcomes Research – Myeloid Malignancies: Poster II Poster: <ul style="list-style-type: none"> • 3629: The Influence of Social Vulnerability on the Prognosis of Chronic Myeloid Leukemia in Adults across the United States (Stanisic AV et al.)
Dec 12 (Monday) 6.00 – 8.00 p.m. Ernest N. Morial Convention	Poster Session: Chronic Myeloid Leukemia Clinical and epidemiological: Poster III Poster: <ul style="list-style-type: none"> • 4324: Single Centre, Retrospective Analysis of Treatment Outcomes and Prognostic Factors in Blastic Phase Chronic Myeloid Leukemia

Time slots	Sessions
Center (Hall D)	<p>(CML-BP) Following Systemic Therapy (Tang K et al.)</p> <ul style="list-style-type: none"> • 4325: Cancer-Related Gene Mutations Drive Resistance to the Third-Generation Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia (Zhang X et al.) • 4326: Treatment-Free Remission Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Following One Year of Nilotinib De-Escalation: 96-Week Update of Dante Study (Stagno F et al.) • 4327: A Risk Model for CML Patients with COVID-19: Importance of Molecular Response in the Context of Age, Comorbidities and Country Income (Radich JP et al.) • 4328: Validation and Use of Predictive Scoring Systems for Molecular Responses in 5,203 Persons with Chronic Myeloid Leukemia (Zhang X et al.) • 4329: Five-Year Overall Survival Analysis Using First- and Second-Generation Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase in a Prospective Observational Study (SIMPLICITY) (Mauro M et al.) • 4330: Outcomes of Chronic Myeloid Leukemia with No Major Molecular Response within 2 Years of Tyrosine Kinase Inhibitor Therapy (Bidikian A et al.) • 4331: Chronic Myeloid Leukemia Reduces Survival in Elderly Patients (Age \geq 75 Years Old): An Israeli Multicenter Retrospective Study (Abulafia AS et al.) • 4332: Digital Droplet (dd) Polymerase Chain Reaction (PCR) Assays Offer Limited Advantages over Conventional Reverse-Transcriptase Quantitative PCR (RT-qPCR) for the Prediction of Molecular Recurrence after Treatment Discontinuation in Chronic Myeloid Leukemia (CML): Results from the Destiny Study (Apperley JE et al.) • 4333: Targeted Next-Generation Sequencing Identifies Additional Mutations Other Than BCR-ABL in Chronic Myeloid Leukemia Patients: A Chinese Monocentric Retrospective Study (Huang J et al.) • 4334: ASC4OPT: A Phase 3b Open-Label Optimization Study of Oral Asciminib in Chronic Myelogenous Leukemia in Chronic Phase Previously Treated with 2 or More Tyrosine Kinase Inhibitors (Breccia M et al.) • 4335: A Predictive Scoring System for Therapy Failure in Persons with Chronic Myeloid Leukemia Receiving Initial a Second-Generation Tyrosine Kinase Inhibitor Therapy (Zhang X et al.) • 4336: Comparison of Generic Dasatinib Versus Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia with

Time slots	Sessions
	<p>Reference to Early Molecular Response: Results from a Single-Center, Randomized Controlled Study from India (Singh SK et al.)</p> <ul style="list-style-type: none"> • 4337: A Phase II, Single-Arm Study of De-Escalation and Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Treated with Nilotinib in First-Line Therapy Followed By a Second Attempt after Nilotinib and Asciminib Combination: Dante Study (Rosti G et al.) • 4338: Five-Year Follow-up of the Phase I/II Discontinuation Trial of Imatinib after Pioglitazone (EDI-PIO) in Chronic Myeloid Leukemia Patients in Deep Molecular Response (Pagnano KB et al.) • 4339: Outcomes in Patients with Chronic Myeloid Leukemia in the Chronic Phase Randomized to Dasatinib or Imatinib after Suboptimal Responses to 3 Months of Imatinib Therapy: Final 5-Year Results from DASCERN (Cortes JE et al.) • 4340: The Multimodal Approach to Evaluating Cardiovascular Risk in Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors- the Role of Endothelial Function (Szczepanek E et al.) • 4341: XS004 Dasatinib (XS004) Improves Variability and Bioavailability in Humans Using Amorphous Solid Dispersion Formulation of Dasatinib with Potential Implications for Its Clinical Use (Lennernäs H et al.) • 4342: Two-Year Updated Results of Asciminib Managed-Access Program (MAP) in Russia (Turkina A et al.) • 4343: Treatment Patterns, Tolerance, and Clinical Response of Chronic Phase Chronic Myeloid Leukemia (CML-CP) Patients (Including Those Harboring the T315I Mutation) Experiencing Multiple Tyrosine Kinase Inhibitor Failure: A Multi-Center Retrospective Chart Review Analysis (Nicolini FE et al.)
<p>Dec 12 (Monday) 6.00 – 8.00 p.m. Ernest N. Morial Convention Center (Hall D)</p>	<p>Poster Session: Outcomes Research – Myeloid Malignancies: Poster III Poster</p> <ul style="list-style-type: none"> • 4949: Impact of Initiating Oral Anticancer Agent Therapy for Chronic Myelogenous Leukemia Among Adults with Multiple Chronic Conditions (Gatwood J et al.)